Ibrutinib has been selected for Medicare price negotiation under the Inflation Reduction Act. The authors summarize the House Oversight Committee investigation to be considered by CMS during the price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback